Trial Profile
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 15 Jul 2017 Results published in the CNS Drugs
- 20 Jun 2017 According to a Shire media release, the U.S. FDA has approved MYDAYIS (mixed salts of a single-entity amphetamine product) for patients 13 years and older with Attention Deficit Hyperactivity Disorder (ADHD), based on the results from 16 studies evaluating Mydayis in more than 1,600 subjects, including adolescents (aged 13-17 years) and adults with ADHD.
- 19 Jan 2017 According to a Shire media release, the U.S. FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. The FDA is expected to provide a decision on or around June 20, 2017, the designated Prescription Drug User Fee Act (PDUFA) action date. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA (May 18, 2007) that requested additional clinical studies.